Ultragenyx (RARE) also reaffirmed its net cash used in operations guidance for 2025, which is expected to modestly increase compared to 2024 and its path to full year GAAP profitability in 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
- Ultragenyx announces first patient dosed in Aurora study
- Ultragenyx’s MPS VII Study: A Closer Look at Market Implications
- Ultragenyx’s Ongoing Study on UX111: A Potential Game-Changer for MPS IIIA Treatment